“In-Pocket” HIV Prevention: New Approach Rivals PrEP, Offers Cost Savings

A 28-day course of on-demand HIV medication, known as post-exposure prophylaxis-in-pocket (PIP), demonstrates comparable effectiveness to daily PrEP (pre-exposure prophylaxis) for individuals at low risk of HIV exposure, according to research presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026. The approach likewise appears to offer healthcare savings and improved quality of life.

Understanding PrEP and PIP

Daily PrEP has been a cornerstone of HIV prevention, but adherence can be a challenge, and it may not be ideal for those with infrequent exposures. PIP offers an alternative: a 28-day course of HIV medication kept readily available for use after a potential exposure. This strategy is particularly relevant for individuals who experience one to four exposures per year.

CROI 2026 Findings

Data presented at CROI 2026 suggests that PIP is a viable option for low-risk individuals. The World Health Organization endorses PIP, allowing individuals to initiate treatment within 72 hours of exposure without requiring an immediate visit to an emergency department or clinic.

Benefits of PIP

• Cost-Effectiveness: PIP may lead to healthcare savings compared to daily PrEP.
• Improved Quality of Life: The on-demand nature of PIP can be more appealing to individuals who are hesitant to commit to daily medication.
• Accessibility: PIP empowers individuals to start treatment promptly after a potential exposure, reducing delays in care.

Expert Perspectives

At CROI 2026, Dr. Andrew Hill from the University of Liverpool highlighted the need to improve PrEP uptake globally, suggesting that strategies like PIP could play a crucial role.

CROI 2026 Conference Details

The 33rd Conference on Retroviruses and Opportunistic Infections (CROI) was held in Denver, Colorado, from February 22 to 25, 2026, and featured presentations on the latest research in HIV and related conditions. Key speakers included Sharon Lewin, Peter Staley, Linda-Gail Bekker, Ilesh Jani, Wesley I. Sundquist, Todd T. Brown, Jeanne M. Marrazzo, Kevin O. Saunders, and Anneke Hesseling. View the full program here.

Looking Ahead

While PIP shows promise, further real-world data are needed to fully understand its long-term effectiveness and impact on HIV transmission rates. The availability of this alternative approach could significantly expand access to HIV prevention for individuals who may not be suitable candidates for daily PrEP.